Skip to main content
. 2017 Feb 24;8(17):27854–27867. doi: 10.18632/oncotarget.15718

Table 3. RAS-RAF codon and other key alterations by TC-6 subgroup.

Gene Total Mutations Total Deletions Most Common Subgroups Count (Percentage) Least Common Subgroups Count (Percentage) Fisher Exact Testp-value
RAS-RAF 311 (38.6%) D1-HRD, CCND1 192/414 (46.4%) D2, MMSET, MAF 115/381 (30.2%) < 0.001
KRAS 134 (16.6%) D1-HRD, MAF 55/261 (21.1%) D2, MMSET, CCND1 77/534 (14.4%) 0.020
G12/13 66 (8.2%) MAF 7/48(14.6%) D1-HRD, D2, CCND1, MMSET 58/747 (7.8%) 0.162
Q61 68 (8.4%) D1-HRD, D2, CCND1 59/658 (9.0%) MMSET, MAF 8/137(5.8%) 0.309
NRAS 151 (18.8%) D1-HRD, D2, CCND1 140/658 (21.3%) MMSET, MAF 11/137 (8.0%) < 0.001
G12/13 26 (3.2%) MMSET, MAF 8/137(5.8%) D1-HRD, D2, CCND1 18/658 (2.7%) 0.107
Q61 125 (15.5%) D1-HRD, D2, CCND1 122/658 (18.5%) MMSET, MAF 3/137(2.2%) < 0.001
BRAF V600E 26 (3.2%) MMSET, MAF 7/137(5.1%) D1-HRD, D2, CCND1 17/658 (2.6%) 0.163
TP53 91 (11.3%) 3 (0.4%) D1-HRD, CCND1, MAF 62/462 (13.4%) D2, MMSET 31/333 (9.3%) 0.093
TRAF3 27 (3.4%) 14 (1.7%) D2, MMSET, MAF 35/381 (9.2%) D1-HRD, CCND1 6/414(1.4%) < 0.001
FGFR3 25 (3.1%) MMSET 25/89 (28.1%) D1-HRD, D2, CCND1, MAF 0/706(0.0%) < 0.001
RB1 23 (2.9%) 15 (1.9%) D2, MMSET 23/333 (6.9%) D1-HRD, CCND1, MAF 15/462 (3.2%) 0.019
CDKN2C 6 (0.7%) 23 (2.9%) D2, MMSET 22/333 (6.6%) D1-HRD, CCND1, MAF 7/462(1.5%) < 0.001
DNMT3A 26 (3.2%) D2, CCND1, MMSET 21/534 (3.9%) D1, MAF 3/261(1.1%) 0.044
ATM/ATR 32 (4.0%) MMSET, MAF 12/137 (8.8%) D1-HRD, D2, CCND1 20/658 (3.0%) 0.006
TET2 23 (2.9%) 1 (0.1%) D2, MAF 12/292 (4.1%) D1-HRD, CCND1, MMSET 11/503 (2.2%) 0.129
BIRC3 2 (0.2%) 21 (2.6%) MMSET 13/89 (14.6%) D1-HRD, D2, CCND1, MAF 10/706 (1.4%) < 0.001

RAS-RAF and other key alterations are not distributed evenly across TC-6 subgroups. We have reported the most significant difference in distribution for each specific gene. A full breakdown of mutation and deletion by subgroup can be found in Supplementary Table 2.

All rows with p-values < 0.01 are bolded. Mutations and deletions are reported in first two columns, and their combined sum (alterations) is divided across the TC-6 subgroups. CCND3-6p21 subgroup is not included in this subgroup analysis due to sample size restraints. For cases with co-occurrence of RAS-RAF mutations, the mutation with highest variant allele frequency is reported here.